对比增强CT后次日随访CT中碘对比剂肾实质滞留的评估
回顾性纳入55例增强CT后次日行随访CT的患者,两位放射科医生按0-6分分类肾实质对比剂滞留模式。37例(67%)出现滞留,弥漫性实质型和肾盂型最常见;增强CT前肌酐和尿素氮升高与滞留显著相关,滞留组对比剂肾病发生率显著高于无滞留组(10/37 vs 0/18,p=0.021)。
要点
- 增强CT后次日随访CT上约67%(37/55)患者可见碘对比剂肾实质滞留,弥漫性实质型和肾盂型最常见。
- 增强CT前肌酐(p=0.018)和尿素氮(p=0.006)升高与肾实质滞留显著相关。
- 滞留组对比剂肾病发生率显著高于无滞留组(10/37 vs 0/18,p=0.021),弥漫性实质型和皮质型在对比剂肾病患者中更常见(p=0.003、p=0.045)。
核心结论
- 增强CT后次日肾实质碘对比剂滞留是常见的影像学表现,且与肾功能异常相关。
- 该表现尤其是弥漫性实质型和皮质型,可能是对比剂肾病发生的潜在生物标志物。
研究设计与样本
- 回顾性研究,纳入55例在增强CT后次日行随访CT的患者。
- 由两位放射科医生将对比剂滞留模式按0-6分分类:0为无滞留,1为弥漫性实质型,2为弥漫性皮质型,3为包膜下微结节型,4为皮质楔形,5为髓质局灶型,6为肾盂型。
- 收集患者临床资料,包括对比剂肾病的发生情况。
关键影像表现/征象
- 37例(67%)患者肾脏出现对比剂滞留(滞留组),18例无滞留(无滞留组)。
- 弥漫性实质型和肾盂型为最常见的滞留模式。
- 弥漫性实质型和弥漫性皮质型在发生对比剂肾病的患者中较未发生者更常见(分别为p=0.003、p=0.045)。
诊断标准与关键数值
- 滞留模式按0-6分分类:0无滞留,1弥漫性实质型,2弥漫性皮质型,3包膜下微结节型,4皮质楔形,5髓质局灶型,6肾盂型。
- 增强CT前肌酐升高与肾实质滞留显著相关(p=0.018)。
- 增强CT前尿素氮升高与肾实质滞留显著相关(p=0.006)。
- 滞留组对比剂肾病发生率为10/37,无滞留组为0/18,两组差异显著(p=0.021)。
临床应用与阅片要点
- 增强CT后次日随访CT时,应关注肾实质是否存在碘对比剂滞留,并按0-6分模式进行分类描述。
- 弥漫性实质型和弥漫性皮质型滞留可能提示对比剂肾病风险,报告中可予以注明。
- 增强CT前肌酐和尿素氮升高的患者更易出现肾实质滞留,阅片时可结合临床肾功能资料综合判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To examine the frequency and patterns of renal parenchymal retention of iodinated contrast agent during follow-up computed tomography (CT) performed one day after undergoing contrast-enhanced CT and to evaluate the association with the renal function before and after contrast-enhanced CT.
MATERIALS AND METHODS: This retrospective study included 55 patients who underwent follow-up CT the day after contrast-enhanced CT had been performed. Two radiologists categorized the retention patterns on a scale of 0-6 (0: no retention, 1: diffuse parenchymal, 2: diffuse cortical, 3: subcapsular tiny nodular, 4: cortical wedge-shaped, 5: medullary focal, 6: renal pelvic). In addition, we collected the patients' clinical data, including the development of contrast-induced nephropathy (CIN).
RESULTS: A total of 37 patients (67 %) showed retention of contrast agent in the kidney (retention group), while 18 did not (non-retention group). A diffuse parenchymal pattern and renal pelvis pattern were the most common. High levels of creatinine (Cre) and blood urea nitrogen (BUN) before contrast-enhanced CT were significantly associated with the retention in the kidney (p = 0.018, 0.006, respectively). The frequency of the development of CIN was significantly higher (p = 0.021) in the retention group (10/37) than in the non-retention group (0/18). A diffuse parenchymal pattern and diffuse cortical pattern were significantly more common in patients with CIN than in those without CIN (p = 0.003, p = 0.045, respectively).
CONCLUSION: Renal parenchymal retention of iodinated contrast agent the day after contrast-enhanced CT was a frequently recognized finding and was associated with renal dysfunction. This finding, especially diffuse parenchymal and cortical patterns, may be a potential biomarker of CIN development.
引用
- Ariyoshi S, Tanabe M, Ito K, et al. Evaluation of the renal parenchymal retention of iodinated contrast agent during follow-up computed tomography performed one day after undergoing contrast-enhanced computed tomography. Eur J Radiol. 2020. PMID: 33164788. doi:10.1016/j.ejrad.2020.109335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。